Pros and Cons of Echocardiography in the Screening,Diagnosis and Follow-up of Patients with Systemic Sclerosis Pulmonary Arterial Hypertension – a Rheumatologist's Perspective

Abstract

Purpose

Our objective was to review the evidence regarding echocardiography in patients with systemic sclerosis (SSc) and possible pulmonary hypertension (PH).

Methods

The literature was reviewed. In addition, a survey was conducted of 315 rheumatologists/internists with a self-declared interest in SSc, to determine their preferred use of echocardiograms.

Results

The most relevant literature findings come from two studies, the DETECT study and one from the Australian Scleroderma Interest Group. In both these studies, it appears that the use of non-echocardiographic variables such as pulmonary function tests (PFTs) and values of serum N-terminal pro-brain natriuretic peptide (NT-proBNP), are adequate on their own in suggesting which patients are at high risk of PH. Echocardiograms added very little information and in fact may confuse the picture by appearing to be normal when in fact underlying PH is present.

With regard to the survey, 157 physicians (49.8%) responded. Of those, 67% felt that an echocardiogram should be ordered on every patient with SSc every year. Ninety-five percent (95%) said the reason was to screen for the development of significant PH, 65% said the reason was to screen for the development of significant intrinsic cardiac disease and 38% said that the reason was to adhere to accepted international recommendations.

Conclusions

Despite popular belief and current recommendations, in the opinion of the author, echocardiograms are not necessary in every SSc patient every year. Cheaper tests such as PFTs and NT-proBNP are adequate in most cases to suggest when a right heart catheterization should be performed.